Global Information
회사소개 | 문의 | 비교리스트

중국의 니코란딜(Nicorandil) 시장(2022-2031년)

Research Report on China´s Nicorandil Market, 2022-2031

리서치사 China Research and Intelligence
발행일 2022년 07월 상품코드 1105812
페이지 정보 영문 50 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 3,600 ₩ 4,717,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 6,290,000 Printable & Editable PDF (Enterprisewide License)


중국의 니코란딜(Nicorandil) 시장(2022-2031년) Research Report on China´s Nicorandil Market, 2022-2031
발행일 : 2022년 07월 페이지 정보 : 영문 50 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

중국의 니코란딜 매출은 2017-2021년간 CAGR 72.4%로 증가해 2021년에 6억 1,800만 위안(9,270만 달러)에 이르렀습니다. 중국에서 판매되고 있는 니코란딜에는 정제와 주사제가 있으며, 후자가 매출 기준 높은 점유율을 차지하고 있습니다.

중국의 니코란딜(Nicorandil) 시장에 대해 조사분석했으며, COVID-19의 영향, 시장 규모, 주요 제조업체 분석, 시장 전망 등에 대한 정보를 제공합니다.

제1장 니코란딜 관련 개념

  • 니코란딜의 적응증
  • 중국의 니코란딜 시장 개발
  • 중국 정부의 니코란딜 승인
  • 중국 니코란딜 시장에 대한 COVID-19의 영향

제2장 중국에서의 니코란딜 판매(2017-2021년)

  • 매출
    • 중국 전체 매출
    • 중국 지역별 매출
  • 판매량
    • 중국 전체 판매량
    • 중국 지역별 판매량
  • 중국의 니코란딜 판매 : 투약 형태별(2017-2021년)
    • 주사
    • 정제

제3장 중국 주요 니코란딜 제조업체 분석(2017-2021년)

  • 시장 점유율 분석
    • 제조업체의 시장 점유율 : 매출별
    • 제조업체의 시장 점유율 : 판매량별
  • Beijing Sihuan Kebao Pharmaceutical Co., LTd.
    • 기업 개요
    • 중국에서의 니코란딜 판매
  • Chugai Pharmaceutical Co., Ltd.
    • 기업 개요
    • 중국에서의 니코란딜 판매
  • Xi'an Hanfeng Pharmaceutical Co., Ltd.
    • 기업 개요
    • 중국에서의 니코란딜 판매
  • Henan Topfond Pharmaceutical Co., Ltd.
    • 기업 개요
    • 중국에서의 니코란딜 판매
  • Shanxi Xin Yu Pharmaceutical Co., Ltd.
    • 기업 개요
    • 중국에서의 니코란딜 판매

제4장 중국 다양한 기업의 니코란딜 판매 가격(2021-2022년)

  • Beijing Sihuan Kebao Pharmaceutical Co., Ltd(RuiKeXi(R))
  • Chugai Pharmaceutical Co., Ltd.(SIGMART(R))
  • Xi'an Hanfeng Pharmaceutical Co., Ltd.(XinDiPin(R))
  • Henan Topfond Pharmaceutical Co., Ltd.(TianFang(R))
  • Shanxi Xin Yu Pharmaceutical Co., Ltd.(YiWanKang(R))

제5장 중국의 니코란딜 시장 전망(2022-2031년)

  • 시장 개발 영향요인
    • 시장에 대한 COVID-19의 영향
    • 시장 성장 촉진요인과 기회
    • 시장 위협과 과제
  • 시장 규모 예측
  • 시장 동향 예측
LSH 22.08.04

List of Charts

  • Chart Patent Information of Nicorandil in China
  • Chart Sales Value and Volume of Nicorandil in China, 2017-2021
  • Chart Sales Value of Nicorandil Injection in China, 2017-2021
  • Chart Sales Value of Nicorandil Tablets in China, 2017-2021
  • Chart Sales Value of Nicorandil Injection in China by Region, 2017-2021
  • Chart Sales Value of Nicorandil Tablets in China by Region, 2017-2021
  • Chart Sales Volume of Nicorandil Injection in China, 2017-2021
  • Chart Sales Volume of Nicorandil Tablets in China, 2017-2021
  • Chart Market Share of Nicorandil Injection Manufacturers in China by Sales Value, 2017-2021
  • Chart Market Share of Nicorandil Tablets Manufacturers in China by Sales Value, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Xi'an Hanfeng Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Henan Topfond Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Price of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Sales Price of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Sales Price of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Nicorandil in China, 2022-2031
  • Chart Forecast on Sales Volume of Nicorandil in China, 2022-2031

In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2021, it is estimated that the number of patients with coronary heart disease in China exceeded 11 million, and that number keeps rising due to environmental pollution and poor lifestyle habits.

Clinically, WHO classifies coronary heart disease into five types: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease), and sudden death.

Angina is a clinical syndrome caused by acute, temporary ischemia and hypoxia of the myocardium due to insufficient blood supply to the coronary arteries. Population-based studies show that the incidence of angina increases with age, with the prevalence increasing from 5%-7% in women aged 45-64 years to 10%-12% in women aged 65-84 years, and from 4%-7% in men aged 45-64 years to 12%-14% in men aged 65-84 years.

The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.

Nicorandil is an anti-anginal drug that both relieves angina symptoms and improves the prognosis of coronary artery disease, with both nitrate-like effects and ATP-sensitive potassium channel-opening effects. It can both dilate large coronary arteries and diastole coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieve angina pectoris. Several global medication guidelines have made high-level recommendations for Nicorandil.

Nicorandil was developed by Chugai with SIGMART as its trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. Nicorandil from Chugai entered the Chinese market in 2009, and generic drugs from local Chinese companies have been marketed since then. in 2017, Nicorandil became reimbursable under the Chinese medical insurance.

CRI's survey data show that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year. Even in the face of COVID-19, the sales value still achieved growth in 2021, reaching CNY618 million (USD92.7 million), with a CAGR of 72.4% from 2017 to 2021. The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

CRI expects that from 2022 to 2031, the number of patients with coronary heart disease and angina will continue to rise in China, and the demand for nicorandil in the Chinese market will keep growing.

Topics covered:

  • The Impact of COVID-19 on China's Nicorandil Market
  • Development Environment of Nicorandil in China
  • Sales Volume and value of Nicorandil in China
  • Sales Volume and Value of Nicorandil in China by Region
  • Major Nicorandil Manufacturers in China and Their Market Share
  • Sales Price of Nicorandil in China
  • Prospects of China's Nicorandil Market, 2022-2031

Table of Contents

1 Relevant Concepts of Nicorandil

  • 1.1 Indications of Nicorandil
  • 1.2 Development of China's Nicorandil Market
  • 1.3 Governmental Approval of Nicorandil in China
  • 1.4 The Impact of COVID-19 on China's Nicorandil Market

2 Sales of Nicorandil in China, 2017-2021

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Nicorandil in China by Dosage Form, 2017-2021
    • 2.3.1 Injection
    • 2.3.2 Tablets

3 Analysis of Major Nicorandil Manufacturers in China, 2017-2021

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Beijing Sihuan Kebao Pharmaceutical Co., Ltd.
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Nicorandil in China
  • 3.3 Chugai Pharmaceutical Co., Ltd.
    • 3.3.1 Company Profile
    • 3.3.2 Sales of Nicorandil in China
  • 3.4 Xi'an Hanfeng Pharmaceutical Co., Ltd.
    • 3.4.1 Company Profile
    • 3.4.2 Sales of Nicorandil in China
  • 3.5 Henan Topfond Pharmaceutical Co., Ltd.
    • 3.5.1 Company Profile
    • 3.5.2 Sales of Nicorandil in China
  • 3.6 Shanxi Xin Yu Pharmaceutical Co., Ltd.
    • 3.6.1 Company Profile
    • 3.6.2 Sales of Nicorandil in China

4 Sales Price of Nicorandil of Different Companies in China, 2021-2022

  • 4.1 Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi®)
  • 4.2 Chugai Pharmaceutical Co., Ltd. (SIGMART®)
  • 4.3 Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin®)
  • 4.4 Henan Topfond Pharmaceutical Co., Ltd. (TianFang®)
  • 4.5 Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang®)

5 Prospects of China's Nicorandil Market, 2022-2031

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend
Back to Top
전화 문의
F A Q